Ionosol ® MB and 5% Dextrose Injection

Manufacturer
ICU Medical Inc.
Effective date
2025-10-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
16
Source
daily-update
Hydrated at
2026-11-07 03:04:39

Label at a glance#

ProductIonosol MB and Dextrose
Active ingredientDEXTROSE MONOHYDRATE, SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, MONOBASIC POTASSIUM PHOSPHATE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Label structure13 sections

Indications and uses

Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight. In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance...

Dosage and administration

The dose is dependent upon the age, weight and clinical condition of the patient. In infants, Ionosol MB and 5% Dextrose Injection is given only after administration of an initial priming solution: 15 mL of half isotonic saline in 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight, administered to small infants at a maximum rate of 0.8 mL/minute. Infants typically tolerate not more than 150 to 200 m...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

(MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP)

A MAINTENANCE ELECTROLYTE SOLUTION

Flexible Plastic Container

Rx only

DESCRIPTION

DESCRIPTION SECTION

Ionosol MB and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is a sterile, nonpyrogenic solution designed for intravenous administration. The solution is formulated to provide fluid and electrolytes for treatment of dehydration and acidosis.

Each 100 mL contains dextrose, hydrous 5 g; sodium lactate, anhydrous 260 mg; potassium chloride 141 mg; magnesium chloride, hexahydrate 30 mg; monobasic potassium phosphate, anhydrous 15 mg; and monobasic sodium phosphate, monohydrate 25 mg.

Each liter contains 25 mEq sodium (Na+); 20 mEq potassium (K+); 3 mEq magnesium (Mg++); 22 mEq chloride (Cl¯); 3 mM of phosphate (PO4≡); and 23 mEq lactate (CH3CH(OH)COO¯).

The electrolyte content is hypotonic (100 mOsmol/L) in relation to the extracellular fluid (1pprox.. 280 mOsmol/L). The osmolarity for the total solution is 352 mOsmol/L (calc.). May contain hydrochloric acid for pH adjustment. pH is 5.0 (4.0 to 6.5).

Dextrose, USP, hydrous is chemically designated C6H12O6 • H2O (D-glucose, monohydrate), a hexose sugar freely soluble in water. Dextrose, hydrous has the following structural formula:

structural formula dextrosestructural formula dextrose

Magnesium Chloride, USP, hexahydrate is chemically designated MgCl2 • 6H2O, colorless flakes or crystals very soluble in water.

Potassium Chloride, USP is chemically designated KCl, a white granular powder freely soluble in water.

Monobasic Potassium Phosphate, NF, anhydrous is chemically designated KH2PO4, colorless crystals or white granular powder freely soluble in water.

Sodium Lactate, USP is chemically designated CH3CH(OH)COONa, a 60% aqueous solution miscible in water.

Monobasic Sodium Phosphate, USP, monohydrate is chemically designated NaH2PO4• H2O, white crystals or granules freely soluble in water.

Water for Injection, USP is chemically designated H2O.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of their chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Ionosol MB and 5% Dextrose Injection contains a hypotonic concentration of electrolytes with dextrose. The letters "MB" mean "modified Butler's" solution; the modified solution contains 5 mEq less sodium, 5 mEq more potassium, and 3 mEq added magnesium, as compared with the original Butler's solution. The modified solution can be used in pediatric patients for treatment of dehydration, acidosis, diarrhea, or burns, and in adults for postoperative fluid and electrolyte therapy.

Solutions containing dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.

The lactate anion provides an alkalizing effect resulting from simultaneous removal by the liver of lactate and hydrogen ions. In the liver, the lactate is metabolized to glycogen which is ultimately converted to carbon dioxide and water by oxidative metabolism.

The lactate anion acts as a source (alternate) of bicarbonate when normal production and utilization of lactic acid is not impaired as a result of disordered lactate metabolism. Since metabolic conversion is dependent on the integrity of cellular oxidative processes, lactate may be inadequate or ineffective as a source of bicarbonate in patients suffering from acidosis associated with shock or other disorders involving reduced perfusion of body tissues. When oxidative activity is intact, one to two hours time is required for metabolism of lactate.

Magnesium chloride in water dissociates to provide magnesium (Mg++) and chloride (Cl‾) ions. Magnesium is the second most plentiful cation of the intracellular fluids. It is an important cofactor for enzymatic reactions and plays an important role in neurochemical transmission and muscular excitability. Normal plasma concentration ranges from 1.5 to 2.5 or 3.0 mEq/liter. Magnesium is excreted solely by the kidney at a rate proportional to the plasma concentration and glomerular filtration.

Phosphate is one of the three major intracellular electrolytes (along with potassium and magnesium) and the largest anion component found within the cells. Its concentration and excretion are largely dependent on intake, acid-base balance and endocrine function. Its metabolism follows that of calcium in many respects. Phosphate anion in electrolyte solutions may help to repair phosphate deficiency.

Potassium chloride in water dissociates to provide potassium (K+) and chloride (Cl‾) ions. Potassium is the chief cation of body cells (160 mEq/liter of intracellular water). It is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a healthy adult and child over 10 days old; 3.5 to 6.0 mEq/liter in a child less than 10 days old). Potassium plays an important role in electrolyte balance. Normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). Average normal pediatric daily requirements are based on the child's weight as described in the table below:

Weight

Fluid Requirements

Up to 10 kg

100 mL/kg

11 to 20 kg

1,000 mL + 50 mL/kg for

each kg above 10 kg

Above 20 kg

1,500 mL + 20 mL/kg for

each kg above 20 kg

Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments, and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

Ionosol MB and 5% Dextrose Injection contains a hypotonic electrolyte concentration. This should not be confused with the total tonicity (electrolytes plus nonelectrolytes) of solutions containing both electrolytes and dextrose. In general, solutions providing isotonic electrolyte concentrations are most applicable to replacement of acute deficits, whereas hypotonic electrolyte concentrations are best suited for parenteral maintenance of water requirements when only small quantities of electrolytes are desired.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight.

In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Solutions containing potassium are contraindicated in diseases where high potassium levels may be encountered.

WARNINGS

WARNINGS SECTION

Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.

Solutions containing lactate ions should be used with great care, if at all, in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of lactate ions, such as severe hepatic insufficiency.

The intravenous administration of Ionosol MB and 5% Dextrose Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

PRECAUTIONS

PRECAUTIONS SECTION

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

Solutions containing lactate ions should be used with caution as excess administration may result in metabolic alkalosis.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Pregnancy Category C.

PREGNANCY SECTION

Animal reproduction studies have not been conducted with Ionosol solutions. It is also not known whether Ionosol solutions can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ionosol solutions should be given to a pregnant woman only if clearly needed.

Geriatric Use:

GERIATRIC USE SECTION

An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Pediatric Use:

PEDIATRIC USE SECTION

The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

OVERDOSAGE SECTION

In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose is dependent upon the age, weight and clinical condition of the patient.

In infants, Ionosol MB and 5% Dextrose Injection is given only after administration of an initial priming solution: 15 mL of half isotonic saline in 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight, administered to small infants at a maximum rate of 0.8 mL/minute. Infants typically tolerate not more than 150 to 200 mL of Ionosol MB and 5% Dextrose Injection per kg body weight/day.

As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

In adults, intravenous infusions of Ionosol MB and 5% Dextrose Injection are given postoperatively, at a rate not greater than 4 mL/minute.

Drug Interactions

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. See PRECAUTIONS.

INSTRUCTIONS FOR USE

To Open:

Tear outer wrap at notch and remove solution container. Some opacity of the plastic due to moisture absorption during sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

If supplemental medication is desired, follow directions below before preparing for administration.

To Add Medication

  1. Prepare additive port.

  2. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.

  3. The additive port may be protected by covering with an additive cap.

  4. Mix container contents thoroughly.

To Administer

  1. Attach administration set per manufacturer's instructions.

  2. Regulate rate of administration per institutional policy.

WARNING: Do not use flexible container in series connections.

HOW SUPPLIED

HOW SUPPLIED SECTION

Ionosol MB and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is supplied in flexible plastic single-dose containers as follows:

NDCFill Volume/Container size (mL)
ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time.
0409-7372-62* 250/250
0990-7372-62* 250/250
0409-7372-03† 500/500
0990-7372-03* , † 500/500

* Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045 USA

† Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045 USA

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.

Revised: August, 2020

ICU Medical, Inc. Lake Forest, Illinois, 60045, USA
IFU0000258

PRINCIPAL DISPLAY PANEL - 500 mL Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

500 mL
NDC 0990-7372-03

IONOSOL® MB and
5% DEXTROSE INJECTION
(MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP)

A MAINTENANCE ELECTROLYTE SOLUTION

EACH 100 mL CONTAINS DEXTROSE, HYDROUS 5 g; MAGNESIUM
CHLORIDE, HEXAHYDRATE 30 mg; POTASSIUM CHLORIDE 141 mg;
MONOBASIC POTASSIUM PHOSPHATE, ANHYDROUS 15 mg; MONOBASIC
SODIUM PHOSPHATE, MONOHYDRATE 25 mg; SODIUM LACTATE,
ANHYDROUS 260 mg.

ELECTROLYTES PER LITER (NOT INCLUDING IONS FOR pH ADJUSTMENT):
SODIUM 25 mEq; POTASSIUM 20 mEq; MAGNESIUM 3 mEq; CHLORIDE 22
mEq; PHOSPHATE 3 mM; LACTATE 23 mEq. MAY CONTAIN HYDROCHLORIC
ACID FOR pH ADJUSTMENT. STERILE, NONPYROGENIC.

352 mOsmol/LITER (CALC.)
pH 5.0 (4.0 to 6.5)

ADDITIVES MAY BE INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF AVAILABLE.
WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO NOT STORE.

SINGLE-DOSE CONTAINER. FOR INTRAVENOUS USE.
USUAL DOSAGE: SEE INSERT. MUST
NOT BE USED IN SERIES CONNECTIONS.

3
V

icumedical

Rx ONLY
CONTAINS DEHP

IM-4445
ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

PRINCIPAL DISPLAY PANEL - 500 mL Bag Label
PRINCIPAL DISPLAY PANEL - 500 mL Bag Label

PRINCIPAL DISPLAY PANEL - Overwrap Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TO OPEN TEAR AT NOTCH

2
HDPE

DO NOT REMOVE FROM OVERWRAP UNTIL READY FOR USE. AFTER REMOVING
THE OVERWRAP, CHECK FOR MINUTE LEAKS BY SQUEEZING CONTAINER FIRMLY.
IF LEAKS ARE FOUND, DISCARD SOLUTION AS STERILITY MAY BE IMPAIRED.
RECOMMENDED STORAGE: ROOM TEMPERATURE (25°C). AVOID EXCESSIVE
HEAT. PROTECT FROM FREEZING. SEE INSERT.
98-4321-R14-3/98

PRINCIPAL DISPLAY PANEL - Overwrap Label
PRINCIPAL DISPLAY PANEL - Overwrap Label

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6e3c022f-0786-43f1-8857-edff89d5153fProduct name120260309
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
efd58652-cb8f-4018-91ca-4b0eb2ff729fProduct name720240226
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
cb89b86a-369e-4204-8910-ae797c503af3Product name120230706
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
2641ccb3-721d-4fbf-9f2f-ca2f18157a62Product name320210309
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
d4880ace-a516-8c47-8dfd-73a4ba5887d7Product name220180830
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
e7e58cd3-cacb-49df-8d34-1ee335614abbProduct name120150609
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0990-7372-03ML - Milliliter0990-7372746fb285-0626-409b-8667-33d35d80403a12020-03-10
0990-7372-62ML - Milliliter0990-7372ac7c0f70-a0d8-4b76-b2cb-2b3a872f118d12019-08-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0990-73720990-7372-62, 0990-7372-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
152025-10-30monthly-update2026-07-17 21:38:12
142025-10-30full-release2026-05-31 22:03:11
122021-03-08full-release2026-05-31 21:16:35

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINERDEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08d4dbc9d85df4…
2026-10-15 13:18:302026-09N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08c2088c7a36db…
2026-09-14 22:38:342026-08N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-0884e616aacf4f…
2026-08-18 06:07:402026-07N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-0831067a03dcf5…
2025-08-23 18:47 UTC2025-08N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-086a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-0803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-082680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-085bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-0879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-081e350fbaab3a…
2024-05-31 18:47 UTC2024-05N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-088072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-085c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-085d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-084b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-0874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-0887673890dc5c…
2021-03-12 10:30 UTC2021-03N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-085aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-088869cabd3fbd…
2020-11-12 02:37 UTC2020-11N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08c0c555d07b60…
2019-12-14 00:12 UTC2019-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-083f01610625f2…
2019-09-15 20:21 UTC2019-09N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08b00525d2431f…
2019-07-19 19:46 UTC2019-07N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-086a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-081c564ffb4f44…
2023-12-20 04:57 UTC2023-12N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-089b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-083f0d92c62455…
2023-05-13 08:27 UTC2023-05N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-08053a50430f4f…
2023-01-26 05:58 UTC2023-01N019513-001IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100MLINJECTABLE / INJECTION1986-05-083bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ionosol MB and DextroseDEXTROSE MONOHYDRATE, SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, POTASSIUM PHOSPHATE, MONOBASIC, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEICU Medical Inc.1b457b1d-0e80-4578-ba6f-dedf513fc9622025-10-30Warnings, Adverse reactionsExact identifier
ndc (package): 0990-7372-03
ndc (package): 0990-7372-62
ndc (product): 0990-7372
ndc11 (package): 00990737203
ndc11 (package): 00990737262
spl id: 7a635ada-cab0-4373-a756-ce80af455324
spl set id: 1b457b1d-0e80-4578-ba6f-dedf513fc962

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.